Ana Ribeiro

Associate Director Immunocore Ltd

Dr Ribeiro is a Research Associate Director at Immunocore, leading a team responsible for the generation of preclinical efficacy and safety data from early stages of drug screening up to candidate nomination and follow up IND/CTA-enabling studies. She has deep knowledge in Immunology and T cell biology, and over 15 years of experience in Research, including pipeline programme leadership. Dr Ribeiro holds a PhD in Biomedical Sciences from University of Porto, Portugal, studying T cell and thymus development.

Seminars

Thursday 10th December 2026
CD1a-Targeted PD-1 Agonists for Localised Immunosuppression in Atopic Dermatitis
11:30 am
  • IMC-U120AI is a novel, first in class skin targeted PD-1 agonist bispecific (ImmTAI) to provide localised immune inhibition for the treatment of Atopic Dermatitis
  • CD1a-targeted PD-1 agonists show potent inhibition of CD4+T-cells and NK cells
  • IMC-U120AI is the first Immunocore ‘universal’ therapy
Ana Ribeiro - speaker for 2nd T-Cell Engager Therapeutics Summit Europe